Vimarsana
Biggest News Aggregation in the World

Page 49 - Accessed May News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed May. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed May Today - Breaking & Trending Today

FDA Authorizes Direct-to-Consumer Test to Detect COVID-19, Influenza, and RSV - Vimarsana News

FDA Authorizes Direct-to-Consumer Test to Detect COVID-19, Influenza, and RSV

The Labcorp test can simultaneously identify and differentiate between influenza A and B, RSV, and SARS-CoV-2.

Legend Biotech: CARVYKTI (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma - Vimarsana News

Legend Biotech: CARVYKTI (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

CARVYKTI is Legend Biotech's first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR)

SpringWorks Therapeutics Highlights Nirogacestat Clinical - Vimarsana News

SpringWorks Therapeutics Highlights Nirogacestat Clinical

- Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or...

Study shows impact of inappropriate antibiotic prescribing on children - Vimarsana News

Study shows impact of inappropriate antibiotic prescribing on children

Researchers found that inappropriate antibiotic prescriptions were associated with avoidable adverse drug events in children, including Clostridioides difficile, and substantial health care expenditures.

Source: healio.com
The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study - Vimarsana News

The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study

/PRNewswire/ -- The European Myeloma Network (EMN), an international collaborative network of expertise centers for multiple myeloma in Europe and Australia,...